PavlÃ-na HaÅ¡kovÃ¡

List of Publications by Year
in descending order

27	708	471509 17	526287 27
papers	citations	h-index	g-index

27	27	27	1129
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comparison of Clinically Used and Experimental Iron Chelators for Protection against Oxidative Stress-Induced Cellular Injury. Chemical Research in Toxicology, 2010, 23, 1105-1114.	3.3	61
2	Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells. PLoS ONE, 2013, 8, e76676.	2.5	58
3	Synthesis and Initial in Vitro Evaluations of Novel Antioxidant Aroylhydrazone Iron Chelators with Increased Stability against Plasma Hydrolysis. Chemical Research in Toxicology, 2011, 24, 290-302.	3.3	52
4	Chronic Anthracycline Cardiotoxicity: Molecular and Functional Analysis with Focus on Nuclear Factor Erythroid 2-Related Factor 2 and Mitochondrial Biogenesis Pathways. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 468-478.	2.5	48
5	Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. British Journal of Pharmacology, 2008, 155, 138-148.	5.4	42
6	Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity. Free Radical Biology and Medicine, 2011, 50, 537-549.	2.9	42
7	Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: Novel iron chelators with selective antiproliferative action. Chemico-Biological Interactions, 2012, 197, 69-79.	4.0	41
8	Antiproliferative effects of selenium compounds in colon cancer cells: Comparison of different cytotoxicity assays. Toxicology in Vitro, 2009, 23, 1406-1411.	2.4	35
9	Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity. Toxicology, 2011, 289, 122-131.	4.2	35
10	Cucurbitacin E Has Neuroprotective Properties and Autophagic Modulating Activities on Dopaminergic Neurons. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-15.	4.0	35
11	Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications. European Journal of Medicinal Chemistry, 2016, 120, 97-110.	5.5	31
12	Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury. Free Radical Biology and Medicine, 2014, 74, 210-221.	2.9	28
13	The Novel Iron Chelator, 2-Pyridylcarboxaldehyde 2-Thiophenecarboxyl Hydrazone, Reduces Catecholamine-Mediated Myocardial Toxicity. Chemical Research in Toxicology, 2009, 22, 208-217.	3.3	27
14	In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity. Archives of Toxicology, 2011, 85, 525-535.	4.2	24
15	HPLC-DAD and MS/MS analysis of novel drug candidates from the group of aromatic hydrazones revealing the presence of geometric isomers. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 295-302.	2.8	23
16	Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically Used Anti-Neoplastic Drugs. PLoS ONE, 2014, 9, e88754.	2.5	23
17	Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicology Research, 2015, 4, 1098-1114.	2.1	20
18	Direct administration of rutin does not protect against catecholamine cardiotoxicity. Toxicology, 2009, 255, 25-32.	4.2	15

#	ARTICLE	IF	CITATIONS
19	Structure-Activity Relationships of Novel Salicylaldehyde Isonicotinoyl Hydrazone (SIH) Analogs: Iron Chelation, Anti-Oxidant and Cytotoxic Properties. PLoS ONE, 2014, 9, e112059.	2.5	15
20	Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury. Toxicology, 2016, 371, 17-28.	4.2	14
21	Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. Toxicology, 2016, 350-352, 15-24.	4.2	10
22	In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PLoS ONE, 2015, 10, e0139929.	2.5	7
23	Intravenous rutin in rat exacerbates isoprenaline-induced cardiotoxicity likely due to intracellular oxidative stress. Redox Report, 2017, 22, 78-90.	4.5	6
24	Design, Synthesis, and Biological Evaluation of Isothiosemicarbazones with Antimycobacterial Activity. Archiv Der Pharmazie, 2017, 350, 1700020.	4.1	5
25	Structureâ€“Activity Relationships of Nitro-Substituted Aroylhydrazone Iron Chelators with Antioxidant and Antiproliferative Activities. Chemical Research in Toxicology, 2018, 31, 435-446.	3.3	5
26	Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-10.	4.0	4
27	Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine. Scientific Reports, 2022, 12, .	3.3	2